Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance
- PMID: 8149355
- DOI: 10.1097/00002826-199402000-00001
Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance
Abstract
The carrier molecule that transports dopamine (DA) across the synaptic membrane is known as the dopamine transporter (DAT). Depending on the ionic conditions, DAT may function as a mediator of both the inward directed DA transport known as the "reuptake" and the outward directed DA transport known as the "release." The functional significance of DAT is in the regulation of DA neurotransmission by terminating the action of DA in the synapse via reuptake. With use of DAT binding as a presynaptic marker to measure altered DA innervation, abnormalities of the DAT binding have been demonstrated in idiopathic Parkinson's disease, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity, and progressive supranuclear palsy. Moreover, the identification of DAT as the neuronal element that mediates the addictive properties of cocaine highlights its significance in cocaine addiction. Cocaine binding in the brain is heterogeneous, and there is an uneven distribution of the high- and low-affinity binding sites across the anatomical regions. Regional differences in ligand binding are observed by using both [3H]cocaine and the diphenyl-substituted piperazine derivatives known as the "GBR series" of ligands. The identification of compounds that inhibit the binding of medications for cocaine abuse. Furthermore, clarification of the various binding domains that may be relevant to transporter function in human neuropsychiatric disorders may lead to the development of new medications for schizophrenia, Tourette's disease, and drug addiction.
Similar articles
-
[The dopamine transporter: characterization and physiopathologic implications].Encephale. 1995 Nov-Dec;21(6):445-51. Encephale. 1995. PMID: 8674469 Review. French.
-
Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum.J Neurochem. 1999 Jan;72(1):148-56. doi: 10.1046/j.1471-4159.1999.0720148.x. J Neurochem. 1999. PMID: 9886065
-
Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.J Med Chem. 2001 Mar 15;44(6):937-48. doi: 10.1021/jm000311k. J Med Chem. 2001. PMID: 11300876
-
Synthesis and transporter binding properties of bridged piperazine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909).J Med Chem. 2000 Dec 14;43(25):4840-9. doi: 10.1021/jm000300r. J Med Chem. 2000. PMID: 11123994
-
Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration.J Neural Transm (Vienna). 2004 Oct;111(10-11):1267-86. doi: 10.1007/s00702-004-0203-2. J Neural Transm (Vienna). 2004. PMID: 15480838 Review.
Cited by
-
Genetic influences on smoking: candidate genes.Environ Health Perspect. 1998 May;106(5):231-8. doi: 10.1289/ehp.98106231. Environ Health Perspect. 1998. PMID: 9647893 Free PMC article. Review.
-
Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area.J Neurosci. 1997 Jun 1;17(11):4037-44. doi: 10.1523/JNEUROSCI.17-11-04037.1997. J Neurosci. 1997. PMID: 9151720 Free PMC article.
-
miR-137 and miR-491 Negatively Regulate Dopamine Transporter Expression and Function in Neural Cells.Neurosci Bull. 2016 Dec;32(6):512-522. doi: 10.1007/s12264-016-0061-6. Epub 2016 Sep 15. Neurosci Bull. 2016. PMID: 27628529 Free PMC article.
-
Age-related decline in motor behavior and striatal dopamine transporter in cynomolgus monkeys.J Neural Transm (Vienna). 2012 Aug;119(8):943-52. doi: 10.1007/s00702-012-0770-6. Epub 2012 Feb 11. J Neural Transm (Vienna). 2012. PMID: 22327353
-
Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.CNS Drugs. 2001;15(4):287-310. doi: 10.2165/00023210-200115040-00004. CNS Drugs. 2001. PMID: 11463134 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources